Del. joins $39.1M price inflation settlement with drug co.; consumers urged to check payout eligibility

Delaware Attorney General Kathy Jennings is encouraging consumers who may have purchased certain generic drugs to check their eligibility for compensation as Delaware joins a multistate effort in seeking preliminary approval for a $39.1 million settlement with the generic drug manufacturer Apotex.

The settlement, which is part of a broader legal action involving all 50 states and territories, addresses allegations that Apotex participated in a conspiracy to inflate drug prices and limit competition, violating antitrust laws.

The settlement was reached in principle last fall, but it required the signatures of all involved states and territories. Now that those signatures have been obtained, the coalition is filing the settlement in a federal court in Connecticut.

Attorney General Jennings is urging Delaware residents to act now, as they may be eligible for restitution.

READ: House Republicans question Governor Meyer’s FY2026 budget protocol

“Delawareans may qualify for restitution under the terms of this multimillion-dollar pharmaceutical settlement,” said AG Jennings. “I urge all consumers and patients to review their rights under this settlement and to act now to claim money that they may be entitled to.”

Consumers who purchased a generic prescription drug between May 2009 and December 2019 could be eligible for compensation. To determine eligibility, individuals can call 1-866-290-0182, email [email protected], or visit www.AGGenericDrugs.com.

In addition to the $39.1 million settlement with Apotex, a separate $10 million settlement was reached with Heritage Pharmaceuticals.

Both companies are accused of engaging in long-running price manipulation and anti-competitive practices involving numerous generic drugs.

As part of the settlement, Apotex and Heritage have agreed to cooperate with ongoing litigation against other corporate defendants and individual executives involved in the conspiracy. Furthermore, both companies will implement internal reforms aimed at ensuring fair competition and compliance with antitrust laws moving forward.

Consumers who may be impacted by these practices are encouraged to check their eligibility for restitution before the claims process closes.